Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Scars

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Manisha PATEL

Baltimore, Maryland, 21231, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female subjects of any race, aged 18 to 50 years inclusive
Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion criteria

Subjects with active inflammatory acne lesions
Subjects with hypertrophic acne scars

Treatment and study plan

Adapalene

Drug

Adapalene Gel 0.3%

Other names: Differin 0.3%

Primary outcomes

Global Scarring Severity

Time frame: Week 24
Grade Level:
- Macular disease
- Mild disease
- Moderate disease
- Severe disease

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.

Important dates

Study start: 2011
Primary completion: 2012
Study completion: 2012
First posted: Oct 1, 2010
Registry last updated: Feb 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed